Credit Suisse Upgrades C4 Therapeutics (CCCC) to Neutral, 'Improved Outlook w/ Multiple Shots on Goal Post 4Q22 EPS'
Tweet Send to a Friend
Credit Suisse analyst Richard Law upgraded C4 Therapeutics (NASDAQ: CCCC) from Underperform to Neutral with a price target of $10.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
